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Introduction {#s1}
============

Polycystic ovary syndrome (PCOS) is one of the most important clinical and public health problems facing women, and has been reported to affect more than 20% of reproductive aged women.^[@R1]^ It has been estimated that the total cost of evaluating and providing care for reproductive-aged PCOS women in the United States is around \$4.36 billion, excluding any potential obstetric complications.^[@R2]^ This syndrome has been found to be associated with significant adverse sequelae that can degrade long-term health and well-being. The short-term morbidities of PCOS include dermatologic, reproductive, and mood disturbances, while the longer-term morbidities of PCOS include vascular dysfunction, neoplastic, and mental health disorders.^[@R3]^ In addition, women with PCOS tend to have other abnormalities, such as: hypertension, dyslipidemia, insulin resistance, impaired glucose tolerance, obesity, and diabetes mellitus. Consequently, women with PCOS are highly susceptible to metabolic syndrome (MetS).^[@R4],[@R5]^ MetS has recently been estimated to have a prevalence of about 23.8%-53.3% among women suffering from PCOS.^[@R6]-[@R8]^ A similar range in the prevalence of MetS components has also been reported.^[@R8]-[@R10]^ The variation in research findings may be due to differences among the participants included in each study, such as: diet, lifestyle and genetic factors. However, one obvious reason for the wide range in the prevalence of MetS is the definition used to diagnose MetS.^[@R11]^ There are a number of definitions of MetS, which mainly differ according to the number of components required and the cut-off points used ([Table 1](#T1){ref-type="table"}).

###### Summary of the MetS definitions

  ----------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------
  **Definitions**                                 **WHO**                                                                **NCEP-ATP III**                                                                  **IDF**                                                                           **EGIR**                               **AACE**                                                                          **AHA/NHLBI**                                                       **ATP III**                                                         **JS 2009**

  Number of Criteria                              Two or more of:                                                        Three or more of:                                                                 Two or more of :                                                                  Two or more of:                        Obesity and two or more of:                                                       Three or more of:                                                   Three or more of:                                                   Three or more of:

  Obesity                                         BMI \> 30 and/or WHR \> 0.9 (men), WHR \> 0.85 (women)                 WC ≥ 102 cm (men), WC ≥ 88 cm (women                                              WC ≥ 94 cm men, WC ≥ 80 cm women                                                  WC ≥ 94 cm\                            WC ≥ 102 cm (men), WC ≥ 88 cm (women                                              BMI ≥ 30 kg/m2                                                      WC ≥ 102 cm (men), WC ≥ 88 cm (women                                Population- and country-specific definitions
                                                                                                                                                                                                                                                                                             (men, WC ≥80 cm (women)                                                                                                                                                                                                                                          

  Blood pressure mm Hg                            ≥ 140/90                                                               ≥ 130/85 or treatment                                                             ≥130/≥85 or treatment                                                             ≥ 140/90                               ≥ 130/85 or treatment                                                             ≥130/85 mm Hg or previous hypertension diagnosis                    ≥ 130/85 or treatment                                               ≥ 130/85 or treatment

  Dyslipidmia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  HDL-C                                           ≥ 35 mg/dL (0.9 mmol/L) in men or ≥ 39 mg/dL (≥ 1.0 mmol/L) in women   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment   ≥ 39 mg/dL (1.0 mmol/L) or treatment   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment

  Triglycerides                                   ≥178 mg/dL(2.0 mmol/L) or treatment                                    ≥150 mg/dL (1.7 mmol/L) or treatment                                              ≥150 mg/dL (1.7 mmol/L) or treatment                                              ≥150 mg/dL (1.7 mmol/L)                ≥150 mg/dL (1.7 mmol/L) or treatment                                              ≥150 mg/dL (1.7 mmol/L) or treatment                                ≥150 mg/dL (1.7 mmol/L)                                             ≥150 mg/dL (1.7 mmol/L) or treatment

  Glucose Intolerance or Fasting Plasma Glucose   ≥110 mg/dL (6.1 mmol/l), DM, IGT, IR                                   ≥100 mg/dL (5.6 mmol/L) or T2D                                                    ≥100 mg/dL (5.6 mmol/L) or T2D                                                    ≥110 mg/dL (6.1 mmol/L)                ≥110 mg/dL (6.1 mmol/l), or treatment                                             ≥100 mg/dL (5.6 mmol/L) or T2D                                      ≥110 mg/dL (6.1 mmol/L)                                             ≥100 mg/dL (5.6 mmol/L) or T2D
  ----------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------

BMI = body mass index; JC= Joint Consensus; DM = diabetes mellitus; EGIR = European Group against Insulin Resistance; HDL-C = high-density lipoprotein cholesterol; IDF = International Diabetes Federation; IGT = impaired glucose tolerance; IR = insulin resistance; NCEP ATPIII = National Cholesterol Education Program Adult Treatment Panel; AACE= American Association of Clinical Endocrinologists; AHA/NHLBI= The American Heart Association / National Heart, Lung, and Blood Institute; JS= Joint Statement; T2 D, type II diabetes mellitus; WC = waist circumference; WHO = World Health Organization; WHR = waist hip ratio.

The relationship between PCOS and MetS has been studied a number of times, with several studies reporting MetS to be more prevalent among women with PCOS than among women of the same age without PCOS.^[@R11]-[@R13]^ In contrast, there are also studies which have reported a higher rate of MetS among healthy women, than among those diagnosed with PCOS.^[@R14]^

In fact, despite a number of studies being conducted in different parts of the world, there has not yet been a comprehensive study of the prevalence of MetS and its components among women diagnosed with PCOS^[@R15]^ Therefore, the objectives of this systematic review and meta-analysis were to: 1) update the prevalence of MetS in women with PCOS, based on commonly used definitions of MetS; 2) determine the prevalence of MetS components among this group of women; and 3) calculate the odds ratio for MetS (using different definitions of MetS) among women with PCOS, in comparison to healthy controls.

Methods {#s2}
=======

Search strategy and study selection {#s2-1}
-----------------------------------

We conducted a systematic review and meta-analysis using the "Preferred Reporting Items for Systematic Reviews and Meta-Analysis" (PRISMA) guidelines.^[@R16]^ The review included all articles published from 2003 to 2016 which measured the prevalence of MetS and/or the components of this syndrome (i.e., waist circumference - WC, blood pressure - BP, high-density lipoprotein cholesterol -HDL-C, triglycerides - TG, fasting blood sugar - FBS) among women diagnosed with PCOS.

The keywords were initially extracted using the medical subject headings (MESH) in Medline, which were: "metabolic syndrome", "dysmetabolic syndrome", "cardiovascular syndrome", "insulin resistance syndrome", "polycystic ovary syndrome", "PCOS", "Prevalence", "odds ratio", "cross-sectional studies", "comparative cross-sectional studies" and "case-control studies". These keywords were then used to search the following databases: PubMed, Web of Science, Medline, Scopus, Embase, CABI, CINAHL, DOAJ, and Index Medicus for Eastern Mediterranean Region-IMEMR. In addition, Google Scholar was used to search the grey literature, as recommended by previous research,^[@R17]^ using the abovementioned search strategy. Finally, in an attempt to gather additional articles, an expert in the subject area was consulted.

Inclusion and exclusion criteria {#s2-2}
--------------------------------

Articles were included from observational studies (cross-sectional, and comparative cross-sectional) which met the following criteria: (a) diagnosis of PCOS using the Rotterdam criteria, which includes women with at least two of the three symptoms (i.e., polycystic ovaries, oligo-ovulation or anovulation and clinical and/or biochemical signs of hyperandrogenism); and (b) MetS, or its components, diagnosed in women with PCOS (or those without PCOS), based upon a standard definition. Original articles were included irrespective of age or race. However, studies were excluded where: (a) an unclear definition of MetS was provided; (b) the data reported were insufficient to determine the prevalence of MetS; and (c) patients were suffering from other clinical disorders. In cases where the data were not included in the published articles, we contacted one of the authors (first/corresponding authors) at least twice in an attempt to obtain the required information.

Data extraction and quality assessment {#s2-3}
--------------------------------------

Two researchers (SS and JH), independently took responsibility for entering data in the review and a third researcher was consulted when any differences were identified. The variables extracted from the articles were: study characteristic (first author's name, date of publication, and country of origin); participant characteristics (gender, age, and sample size); MetS prevalence, as well as the definition(s) used; and the prevalence of MetS components (WC, BP, HDL-C, TG, FBS). The quality of the study was also measured using the STROBE checklist (22 items). Those which met the minimum acceptable quality criteria (\>15 items) were included in the analysis.^[@R18]^ It is important to mention that the risk was assessed using the Newcastle--Ottawa scale.^[@R19]^ The research design, recruitment strategy, response rate, representativeness of the sample, objectivity of the outcome, power calculation provided, and appropriate statistical analyses were also evaluated.^[@R19]^ The minimum and maximum scores were 0 and 9, respectively. The studies were then categorized as low risk (≥6), moderate risk (\<6 but \>3) and high risk (\<3).

Statistical analysis {#s2-4}
--------------------

A random-effects model was used to analyze the prevalence of MetS, and its components, among women with PCOS. An odds ratio (OR) was used to illustrate the association between MetS and PCOS, also using a random effects model. Heterogeneity between studies was examined using the I^2^ index and a random-effects model was again used where heterogeneity was identified (I^2^\> 0.6). Meta-regression was used to identify the source of heterogeneity and publication bias was investigated using a funnel plot and Egger's test.^[@R20]^ All statistical tests were conducted using Review Manager (RevMan) version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and Stata software version 13 (Stata Corp, College Station, TX, USA).

Results {#s3}
=======

A total of 1458 records were identified through the combined search of the databases. However, following elimination of the non-eligible studies, a total of 72 cross-sectional studies and 35 comparative cross-sectional studies were retained to estimate the prevalence and risk of MetS among women with PCOS. [Figure 1](#F1){ref-type="fig"} depicts the flow chart used in the study selection. Articles were identified from 20 different countries during the period 2003-2015, with the majority of these originating from the United States. Surprisingly, there were no articles identified from Africa. The age range of individuals who had taken part in these studies ranged from 15-54 years old. The MetS definition used in this study was based on the NCEP-ATP III criteria. The characteristics of the studies included in this research are reported in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.
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###### Prevalence of metabolic syndrome in women with and without PCOS

  ------------------ ---------------- ---------------------- ---------------- ---------------------- ----------------------------------------- -------------------------------------------- ---------------- ------ ------- ------ ------ ------- ----------
  **First Author**   **Country**      **Criteria**           **Study year**   **Publication Year**   **Characteristics of People with PCOS**   **Characteristics of People without PCOS**   **Reference**                                         
  **Age Range**      **Mean Age**     **Total Sample**       **Prev. MetS**   **Age Range**          **Mean Age**                              **Total Sample**                             **Prev. MetS**                                        
  Kyrkou G           Greece           IDF                    \-               2015                   \-                                        24.7                                         230              12.6   \-      24.1   155    1.9     ^[@R21]^
  Romanowski MD      Brazil           NCEP-ATP III           2008-2009        2015                   \-                                        26.8                                         101              32.7   \-      33.7   77     19.5    ^[@R22]^
  Romanowski MD      Brazil           IDF                    2008-2009        2015                   \-                                        26.8                                         101              44.6   \-      33.7   77     28.6    ^[@R22]^
  Pillai BP          India            IDF                    2010-2012        2015                   12-41                                     24.8                                         121              52.0   \-      \-     \-     \-      ^[@R23]^
  Pillai BP          India            NCEP-ATP III           2010-2012        2015                   12-41                                     24.8                                         121              30.6   \-      \-     \-     \-      ^[@R23]^
  Madani T           Iran             NCEP-ATP III                            2015                   \-                                        28.6                                         624              19.7   \-      \-     \-     \-      ^[@R24]^
  Shabir I           India            IDF                    2009-2010        2014                   13-28                                     23.0                                         37               27.0   \-      \-     \-     \-      ^[@R25]^
  Shabir I           India            ATP III                2009-2010        2014                   13-28                                     23.0                                         37               22.0   \-      \-     \-     \-      ^[@R25]^
  Figurova J         Slovakia         NCEP-ATP III           2010-2013        2014                   20-41                                     29.2                                         99               21.2   \-      \-     \-     \-      ^[@R26]^
  Tehrani FR         Iran             IAMC                   2010-2012        2014                   18-45                                     29.1                                         85               7.1    \-      33.9   517    19.53   ^[@R27]^
  Rong Li            China            NCEP-ATP III           \-               2014                   19-45                                     29.1                                         833              19.1   \-      32.3   2732   14.7    ^[@R28]^
  Kim MJ             Korea            NCEP-ATP III           2010-2011        2014                   15-40                                     27.9                                         837              16.7   \-      \-     \-     \-      ^[@R29]^
  Panidis D          Greece           NCEP-ATP III           \-               2013                   \-                                        24.7                                         1223             15.8   \-      31.3   277    10.1    ^[@R30]^
  Panidis D          Greece           AHA-NHLBI              \-               2013                   \-                                        24.7                                         1223             23.9   \-      31.3   277    18.8    ^[@R30]^
  Panidis D          Greece           IDF                    \-               2013                   \-                                        24.7                                         1223             28.9   \-      31.3   277    23.8    ^[@R30]^
  Panidis D          Greece           Joint Defintion        \-               2013                   \-                                        24.7                                         1223             29.5   \-      31.3   277    23.8    ^[@R30]^
  Mandrelle K        India            Modified AHA ATP III   2009-2010        2012                   19-38                                     26.1                                         120              37.5   \-      \-     \-     \-      ^[@R31]^
  Moini A            Iran             NCEP-ATP III           2008-2009        2012                   15-40                                     28.0                                         282              22.7   \-      \-     \-     \-      ^[@R32]^
  Verit FF           Turkey           NCEP-ATP III           2004-2010        2012                   18-34                                     26.0                                         163              25.7   \-      26.3   53     26.3    ^[@R33]^
  Ishak A            Malaysia         IDF                    2008-2010        2012                   18-41                                     29.6                                         99               43.4   \-      \-     \-     \-      ^[@R34]^
  Bhattacharya SM    India            JS 2009                2007-2008        2011                   \-                                        17.0                                         96               60.8   \-                            ^[@R35]^
  Mehrabian F        Iran             NCEP-ATP III           2006-2008        2011                   18-42                                     \-                                           539              24.9   \-      \-     \-     \-      ^[@R36]^
  Hudecova M         Sweden           NCEP-ATP III           \-               2011                   15-46                                     43.0                                         84               23.8   \-      43.7   87     8.0     ^[@R6]^
  VrbÍková J         Czech Republic   IDF                    \-               2011                   22-28                                     16.8                                         43               11.6   22-27   17.5   48     2.1     ^[@R37]^
  Gangale MF         Italy            ATP III                \-               2011                   22-31                                                                                  140              18.6   \-      \-     \-     \-      ^[@R38]^
  Hosseinpanah F     Iran             JS                     2009-2010        2011                   25-39                                     31.0                                         136              15.4   30-41   36.0   423    17.1    ^[@R39]^
  Dey R              India            NCEP-ATP III           2006--2007       2011                   15-35                                                                                  50               42.0   \-      \-     \-     \-      ^[@R40]^
  Bhattacharya SM    India            IDF                    2004-2006        2010                   15-40                                     22.1                                         198              47.5   \-      \-     \-     \-      ^[@R41]^
  Bhattacharya SM    India            ATP III                2004-2006        2010                   \-                                        22.2                                         198              37.9   \-      \-     \-     \-      ^[@R41]^
  Indhavivadhana S   Thailand         NCEP-ATP III           2007             2010                   \-                                        25.4                                         250              18.0   \-      \-     \-     \-      ^[@R42]^
  Indhavivadhana S   Thailand         IDF                    2007             2010                   \-                                        25.4                                         250              21.2   \-      \-     \-     \-      ^[@R42]^
  Indhavivadhana S   Thailand         AHA/NHLBI              2007             2010                   \-                                        25.4                                         250              21.2   \-      \-     \-     \-      ^[@R42]^
  Fruzzetti F        Italy            Ferranti               2006-2007        2009                   12-19                                     17.2                                         53               9.4    \-      \-     \-     \-      ^[@R43]^
  Moradi S           Iran             ATP III                \-               2009                   16-48                                     28.0                                         151              46.4   \-      \-     \-     \-      ^[@R44]^
  Ni R               China            IDF                    2004-2008        2009                   20-41                                     27.0                                         578              16.8   \-      \-     \-     \-      ^[@R45]^
  Gambineri A        Italy            NCEP-ATP III           \-               2009                   14-49                                     26.1                                         200              32.0   14-49   26.8   200    23.0    ^[@R46]^
  Gambineri A        Italy            IDF                    \-               2009                   14-49                                     26.1                                         200              39.0   14-49   26.8   200    25.0    ^[@R46]^
  Gambineri A        Italy            AHA/NHLBI              \-               2009                   14-49                                     26.1                                         200              37.0   14-49   26.8   200    24.0    ^[@R46]^
  Soares EMM         Brazil           NCEP-ATP III           2004-2005        2008                   20-34                                     26.4                                         102              28.4   \-      \-     \-     \-      ^[@R47]^
  Attaoua R          Romania          NCEP-ATP III           \-               2008                   19-57                                     23.1                                         107              15.8   \-      34.1   100    4.0     ^[@R48]^
  Cheung LP          China            ATP III (Modified)     2003-7           2008                   \-                                        30.2                                         295              24.9   \-      \-     \-     \-      ^[@R49]^
  Cussons AJ         Australia        WHO                    2000-5           2008                   25-54                                     34.3                                         168              33.3   25-53   33.7   883    \-      ^[@R50]^
  Cussons AJ         Australia        NCEP-ATP III           2000-5           2008                   25-54                                     34.3                                         168              36.9   25-53   33.7   883    10.0    ^[@R50]^
  Cussons AJ         Australia        IDF                    2000-5           2008                   25-54                                     34.3                                         168              39.9   25-53   33.7   883    13.5    ^[@R50]^
  Gulcelik NE        Turkey           NCEP-ATP III           \-               2008                   \-                                        24.6                                         30               33.3   \-      26.1   60     11.7    ^[@R51]^
  Costa L            Brazil           NCEP-ATP III           2005-6           2007                   19-38                                     24.1                                         90               30.4   19-38   30.9   44     6.8     ^[@R52]^
  Costa L            Brazil           IDF                    2005-6           2007                   19-38                                     24.1                                         90               32.6   19-38   30.9   44     9.1     ^[@R52]^
  Weerakiet S        Thailand         IDF                    2002-5           2007                   \-                                        28.8                                         170              35.3   \-      \-     \-     \-      ^[@R53]^
  Marcondes JAM      Brazil           NCEP-ATP III           1995-2004        2007                   \-                                        25.0                                         73               38.4   \-      \-     \-     \-      ^[@R54]^
  Caliskan E         Turkey           NCEP-ATP III           2004-6           2007                   \-                                        23.2                                         182              8.2    \-      23.6   182    2.7     ^[@R55]^
  Caliskan E         Turkey           IDF                    2004-6           2007                   \-                                        23.2                                         182              14.3   \-      23.6   182    2.7     ^[@R55]^
  Caliskan E         Turkey           WHO                    2004-6           2007                   \-                                        23.2                                         182              8.2    \-      23.6   182    2.7     ^[@R55]^
  Caliskan E         Turkey           AHA/NHLBI              2004-6           2007                   \-                                        23.2                                         182              10.4   \-      23.6   182    6.6     ^[@R55]^
  Shroff R           USA              AHA                    \-               2007                   \-                                        32.0                                         24               25.0   \-      24.0   36     17.0    ^[@R56]^
  Park HR            Korea            NCEP-ATP III           \-               2007                   16-39                                     26.0                                         113              14.5   30-80   46.9   774    4.3     ^[@R7]^
  Hahn S             Germany          NCEP-ATP III           \-               2006                   \-                                        28.0                                         411              33.8   \-      28.0   82     7.3     ^[@R57]^
  Carmina E          USA              ATP III                1991-2004        2006                   18-40                                     24.9                                         282              8.2    \-      25.2   85     2.4     ^[@R11]^
  Carmina E          USA              WHO                    1991-2004        2006                   18-40                                     24.9                                         282              16.0   \-      25.2   85     2.4     ^[@R11]^
  Ehrmann DA         USA              ATP III                \-               2006                   18-41                                     28.4                                         368              33.4   \-      \-     \-     \-      ^[@R10]^
  Alvarez-Blasco F   Spain            ATP III                2002-5           2006                   \-                                        26.0                                         32               25.0   \-      32.0   72     26.0    ^[@R58]^
  Coviello AD        USA              Cook                   \-               2006                   14-19                                     17.0                                         49               37.0   \-      \-     \-     \-      ^[@R59]^
  Coviello AD        USA              Ferranti               \-               2006                   14-19                                     17.0                                         49               47.0   \-      \-     \-     \-      ^[@R59]^
  Leibel NL          USA              C-III                  \-               2006                   12-19                                     16.0                                         36               19.4   \-      \-     \-     \-      ^[@R60]^
  Leibel NL          USA              C-04                   \-               2006                   12-19                                     16.0                                         36               27.8   \-      \-     \-     \-      ^[@R60]^
  Apridonidze T      USA              NCEP-ATP III           2000-3           2005                   20-40                                     29.9                                         106              43.0   \-      \-     \-     \-      ^[@R12]^
  Dokras A           USA              ATP III                2002             2005                   18-49                                     28.0                                         129              47.3   18-50   44.0   177    6.8     ^[@R4]^
  Rabelo-Acevedo M   Puerto Rico      ATP III                \-               2005                   19-57                                     29.4                                         39               44.0   \-      \-     \-     \-      ^[@R61]^
  Vrbikova J         Czech Republic   ATP III                2001-3           2005                   22-28                                     24.0                                         69               1.6    22-27   23.8   73     0       ^[@R37]^
  Vural B            Turkey           NCEP-ATP III           2002-4           2005                   18-22                                     21.4                                         43               2.3    18-22   20.8   43     0       ^[@R62]^
  Vural B            Turkey           WHO                    2002-4           2005                   18-22                                     21.4                                         43               11.6   18-22   20.8   43     0       ^[@R62]^
  Faloia E           Italy            NCEP-ATP III           \-               2004                   \-                                        22.0                                         50               8.0    \-      \-     \-     \-      ^[@R63]^
  Glueck CJ          USA              ATP III                \-               2003                   \-                                        31.0                                         138              46.4   \-      \-     1887   22.8    ^[@R64]^
  ------------------ ---------------- ---------------------- ---------------- ---------------------- ----------------------------------------- -------------------------------------------- ---------------- ------ ------- ------ ------ ------- ----------

###### Prevalence of Metabolic Syndrome Components in Women with PCOS

  ------------------ ---------------- ---------------------- ---------------- ---------------------- ----------------------------------------- ----------------- ---------------- ------ ------ ------ ------ ------ ----------
  **First Author**   **Country**      **Criteria**           **Study year**   **Publication Year**   **Characteristics of people with PCOS**   **Ref.**                                                              
  **Age range**      **Mean age**     **Total sample**       **Pr. WC (%)**   **Pr. HTN (%)**        **Pr. HDL (%)**                           **Pr. FBS (%)**   **Pr. TG (%)**                                      
  Kyrkou G           Greece           IDF                    \-               2015                   14--44                                    24.7              230              72.2   12.6   26.1   7.0    10.4   ^[@R21]^
  Madani T           Iran             NCEP-ATP III           2012-2013        2015                   \-                                        28.6              624              34.6   2.2    71.5   13.1   26.0   ^[@R24]^
  Shabir I           India            IDF                    2009-2010        2014                   13-28                                     23.0              37               67.5   22.0   NE     36.0   48.0   ^[@R25]^
  Shabir I           India            ATP III                2009-2010        2014                   13-28                                     23.0              37               67.5   22.0   NE     36.0   48.0   ^[@R25]^
  Rong Li            China            NCEP-ATP III           \-               2014                   19-45                                     29.1              833              84.8   45.7   85.9   55.0   63.4   ^[@R28]^
  Mandrelle K        India            Modified AHA ATP III   2009-2010        2012                   19-38                                     26.1              120              45.8   20.0   91.7   8.3    \-     ^[@R31]^
  Moini A            Iran             NCEP-ATP III           2008-2009        2012                   15-40                                     28.0              282              31.0   10.6   68.8   3.2    33.0   ^[@R32]^
  Verit FF           Turkey           NCEP-ATP III           2004-2010        2012                   18-34                                     26.0              163              26.4   17.8   42.3   12.3   22.1   ^[@R33]^
  Hudecova M         Sweden           NCEP-ATP III           \-               2011                   15-46                                     43.0              84               46.4   NE     NE     8.3    21.4   ^[@R6]^
  Hosseinpanah F     Iran             JIS                    2009-2010        2011                   18-45                                     31.0              136              81.0   NE     95.2   NE     87.7   ^[@R39]^
  Bhattacharya SM    India            IDF                    2004-2006        2010                   \-                                        22.1              198              NE     68.1   98.9   68.1   98.9   ^[@R35]^
  Bhattacharya SM    India            ATP III                2004-2006        2010                   \-                                        22.2              198              NE     52.0   98.7   52.0   98.7   ^[@R35]^
  Indhavivadhana S   Thailand         NCEP-ATP III           2007             2010                   \-                                        25.4              250              48.8   14.0   39.6   6.8    17.2   ^[@R42]^
  Indhavivadhana S   Thailand         IDF                    2007             2010                   \-                                        25.4              250              48.8   14.0   39.6   6.8    17.2   ^[@R42]^
  Indhavivadhana S   Thailand         AHA/NHLBI              2007             2010                   \-                                        25.4              250              48.8   14.0   39.6   6.8    17.2   ^[@R42]^
  Fruzzetti F        Italy            Ferranti               2006-2007        2009                   12-19                                     17.2              53               28.3   28.3   43.4   1.9    7.5    ^[@R43]^
  Moradi S           Iran             ATP III                \-               2009                   16-48                                     28.0              151              55.6   23.0   71.0   7.3    48.0   ^[@R44]^
  Ni R               China            IDF                    2004-2008        2009                   20-41                                     27.0              578              38.4   16.1   41.6   19.8   41.6   ^[@R45]^
  Gambineri A        Italy            NCEP-ATP III           \-               2009                   14-49                                     26.1              200              57.0   50.0   58.0   6.0    11.0   ^[@R46]^
  Gambineri A        Italy            IDF                    \-               2009                   14-49                                     26.1              200              57.0   50.0   58.0   17.0   11.0   ^[@R46]^
  Gambineri A        Italy            AHA/NHLBI              \-               2009                   14-49                                     26.1              200              57.0   50.0   58.0   17.0   11.0   ^[@R46]^
  Soares EMM         Brazil           NCEP-ATP III           2004-2005        2008                   20-34                                     26.4              102              57.9   18.6   69.6   2.9    31.7   ^[@R47]^
  Cheung LP          China            ATP III (Modified)     2003-7           2008                   \-                                        30.2              295              53.1   29.4   28.6   21.4   21.4   ^[@R49]^
  Gulcelik NE        Turkey           NCEP-ATP III           \-               2008                   \-                                        24.6              30               21.0   6.0    48.0   2.0    17.0   ^[@R51]^
  Costa L            Brazil           NCEP-ATP III           2005-6           2007                   19-38                                     24.1              90               47.8   28.2   52.2   4.3    8.7    ^[@R52]^
  Costa L            Brazil           IDF                    2005-6           2007                   19-38                                     24.1              90               47.8   28.2   52.2   4.3    8.7    ^[@R52]^
  Weerakiet S        Thailand         IDF                    2002-5           2007                   \-                                        28.8              170              55.9   28.2   59.4   23.5   25.9   ^[@R53]^
  Marcondes JAM      Brazil           NCEP-ATP III           1995-2004        2007                   \-                                        25.0              73               49.3   24.7   67.6   6.9    31.8   ^[@R54]^
  Caliskan E         Turkey           NCEP-ATP III           2004-6           2007                   \-                                        23.2              182              19.2   15.4   61.0   5.5    5.5    ^[@R55]^
  Caliskan E         Turkey           IDF                    2004-6           2007                   \-                                        23.2              182              19.2   15.4   61.0   5.5    5.5    ^[@R55]^
  Caliskan E         Turkey           WHO                    2004-6           2007                   \-                                        23.2              182              19.2   15.4   61.0   5.5    5.5    ^[@R55]^
  Caliskan E         Turkey           AHA/NHLBI              2004-6           2007                   \-                                        23.2              182              19.2   15.4   61.0   5.5    5.5    ^[@R55]^
  Park HR            Korea            NCEP-ATP III           \-               2007                   16-39                                     26.0              113              24.0   20.2   45.1   0.9    13.3   ^[@R7]^
  Hahn S             Germany          NCEP-ATP III           \-               2006                   \-                                        28.0              411              74.4   45.5   44.8   15.1   23.4   ^[@R57]^
  Carmina E          USA              ATP III                1991-2004        2006                   18-40                                     24.9              282              39.0   7.3    45.1   3.1    9.3    ^[@R11]^
  Carmina E          USA              WHO                    1991-2004        2006                   18-40                                     24.9              282              39.0   7.3    45.1   3.1    9.3    ^[@R11]^
  Ehrmann DA         USA              ATP III                \-               2006                   18-41                                     28.4              368              80.0   21.0   66.0   5.0    32.0   ^[@R10]^
  Alvarez-Blasco F   Spain            ATP III                2002-5           2006                   \-                                        26.0              32               66.0   25.0   72.0   6.0    19.0   ^[@R58]^
  Coviello AD        USA              Cook                   \-               2006                   14-19                                     17.0              49               47.0   41.0   84.0   2.0    49.0   ^[@R59]^
  Coviello AD        USA              Ferranti               \-               2006                   14-19                                     17.0              49               65.0   41.0   84.0   2.0    53.0   ^[@R59]^
  Apridonidze T      USA              NCEP-ATP III           2000-3           2005                   20-39                                     29.9              106              67.0   45.0   68.0   3.8    35.0   ^[@R12]^
  Rabelo-Acevedo M   Puerto Rico      ATP III                \-               2005                   19-57                                     29.4              39               89.5   36.0   71.0   \-     43.0   ^[@R61]^
  Vrbikova J         Czech Republic   ATP III                2001-3           2005                   22-28                                     24.0              64               11.0   13.0   34.8   0.0    5.8    ^[@R37]^
  Glueck CJ          USA              ATP III                \-               2003                   \-                                        31.0              138              85.5   44.9   64.5   5.1    32.6   ^[@R64]^
  ------------------ ---------------- ---------------------- ---------------- ---------------------- ----------------------------------------- ----------------- ---------------- ------ ------ ------ ------ ------ ----------

Prevalence of MetS and its component in women with PCOS {#s3-1}
-------------------------------------------------------

The pooled prevalence of MetS among PCOS women was found to be 26.30% (95% CI: 23.68--28.93). However, the pooled prevalence differed according to the definition of MetS used and were as follows: NCEP-ATP III (23.52%, 95% CI:20.21-26.83); IDF (30.81, 95% CI: 24.69--36.93); ATP III (29.36, 95% CI: 19.36--39.36); IMAC (7.10 , 95% CI: 1.64--12.56); JS (34.67, 95% CI: 16.77--52.58); Modified AHA-ATPIII (37.50, 95% CI: 28.84--46.16); AHA-NHLBI (23.12, 95% CI: 14.98--31.26); Ferranti (27.74%, 95% CI: 9.10--64.57); WHO (17.16, 95% CI: 7.28--27.05); Cook (37.00, 95% CI: 23.48--50.52); C-III (19.40, 95% CI: 6.48--32.32); and C-04 (27.80, 95% CI: 13.17--42.43) ([Figure 2](#F2){ref-type="fig"}).

![](jcvtr-10-56-g002){#F2}

The pooled prevalence of MetS components in women diagnosed with PCOS are presented in online Figure S1-S5 (See [Supplementary file 1](#Suppl1){ref-type="supplementary-material"}). The prevalence of the individual components of MetS in women diagnosed with PCOS were: high FBS - 13.44% (95% CI: 9.05--17.84), low HDL - 61.87% (95% CI: 53.31--70.43), HTN - 26.69% (95% CI: 20.34--33.3), high TG - 33.09% (95% CI: 18.82--47.35) and high WC - 52.23% (95% CI: 43.84--60.61).

Association between PCOS and MetS {#s3-2}
---------------------------------

This meta-analysis also estimated the odds of MetS in woman diagnosed with PCOS and compared the prevalence of MetS with healthy women (i.e., not diagnosed with PCOS) using comparative cross-sectional studies. Additionally, the association between PCOS and MetS was examined using OR. In general, the odds of being diagnosed with MetS increased two fold for those diagnosed with PCOS (OR=2.09, 95% CI: 1.67--2.60), in comparison with the healthy controls. This OR varied widely, according to the MetS definition used, and included the following: NCEP-ATP III - 2.60 (95% CI: 1.77--3.84); IDF - 2.28 (95% CI: 1.33--3.89); IAMC - 0.31(95% CI: 0.13--0.74); AHA-NHLBI - 1.54 (95% CI: 1.21--1.96); JS - 1.16 (95% CI: 0.79--1.70); WHO - 4.69 (95% CI: 2.09--10.52); and ATP III - 2.23 (95% CI: 1.14--4.38) ([Figure 3](#F3){ref-type="fig"}).

![](jcvtr-10-56-g003){#F3}

Heterogeneity and Meta-regression {#s3-3}
---------------------------------

Due to the significant heterogeneity in the ORs reported by the different studies (χ^2^=1251.39 *df*=71 *P*\<0.00001 and I^2^=94%), a number of variables were entered into a meta-regression model in order to identify the source (s) of the heterogeneity. *Criteria*, *publication date*, *continent* and *age* were examined in this model, but only *criteria* and *Publication date* were statistically significant (*P*\<0.001) ([Table 4](#T4){ref-type="table"}).

###### Association between studied covariates with the MetS odds ratio among PCOS patients, compared to healthy controls

  ------------------- ---------------------- ---------
  **Variables**       **Meta-regression**    
  **Univariate**      **Multivariate** ^a^   
  ***P*** **value**   ***P*** **value**      
  Criteria            0.004                  0.001
  Publication date    \<0.001                \<0.001
  Continent           0.95                   
  Mean age            0.68                   \-
  ------------------- ---------------------- ---------

^a^Between-study variance assessed by moment-based estimate (tau2= 0.22).

Therefore, a subgroup analysis was conducted using publication date and diagnostic criteria used. The subgroup analysis also confirmed the results of the meta-regression, in that the OR for the relationship between PCOS and MetS was found to be different according to the research period, with studies conducted during 2003-2010 having a higher OR (OR = 3.02; 95% CI: 2.32-3.93) than those conducted from 2011-2015 (OR = 1.27; 95% CI: 1.03-1.58). Interestingly, the more recent studies reported a weaker association between PCOS and MetS than the earlier studies.

Publication bias {#s3-4}
----------------

The publication bias in relation to the OR for MetS among women diagnosed with PCOS (compared to the healthy controls) was examined using funnel plots and Egger's test. [Figure 4](#F4){ref-type="fig"} shows that there was no significant publication bias (*P*=0.112). Notably, the risk of bias assessment showed that the majority of the studies included had acceptable validity and no study was found to have a score lower than 3 (Table S1, online [Supplementary file 1](#Suppl1){ref-type="supplementary-material"}).

![](jcvtr-10-56-g004){#F4}

Discussion {#s4}
==========

This study found that the general prevalence of MetS in women with PCOS varied according to the definition used. The highest prevalence of 37.50% was identified using the modified AHA ATP III definition, while the lowest prevalence was 7.10%, using the IAMC definition. Similar differences have also been observed in other studies.^[@R30],[@R55]^

Using a cross-sectional study, the prevalence of MetS in patients with PCOS, based on the WHO criteria, was found to be 33%. However, using the NCEP-ATP-III and IDF criteria, these estimates were found to be 37% and 40%, respectively.^[@R50]^ These findings support previous research, which also found the IDF criteria to be more sensitive than the NCEP-ATP III criteria in identifying PCOS subjects with MetS (52% vs. 30.6%).^[@R23]^ The present findings also supported research by Bhattacharya, which found the prevalence of MetS among women with PCOS to be 37.9% and 47.5% using the NCEP-ATP III and IDF criteria, respectively.^[@R65]^ In another study, which used four definitions of MetS (NCEP-WHO-AHA/NCLBI-IDF), the IDF definition was again found to be the most sensitive in identifying MetS cases. This might be the result of the lower values of both waist circumference and FBS levels used in the IDF criteria.^[@R55]^

The present study found a significant relationship between PCOS and MetS (OR=2.09), which ranged from 0.31 to 4.69, depending upon the definition of MetS used. This association has been examined previously by a number of studies.^[@R30],[@R50],[@R55]^ For instance, research using the NCEP-ATP III definition reported a higher prevalence of MetS in women suffering from PCOS than among healthy controls.^[@R30]^ The same study also reported that there was no significant relationship between PCOS and MetS when using the AHA/NHLBI, IDF and Joint definitions.^[@R30]^ Moreover, Çalışkan et al. showed a greater prevalence of MetS among patient with PCOS, than in the control group, when using all criteria except for AHA/NCLBI.^[@R55]^ In addition, another study reported a 4-fold increased prevalence of MetS in PCOS-suffering women, compared to the overall population.^[@R50]^ Previous research has also found a much greater likelihood (4.2- fold) of developing MetS among adolescent Indian girls with PCOS, when compared to those without PCOS.^[@R35]^ In contrast, Hosseinpanah et al did not find a significantly higher frequency of MetS in a sample of Iranian women with PCOS, than that found in healthy subjects.^[@R39]^

Therefore, there is great variation in the prevalence of MetS, even among studies which used the same definition of PCOS. This variability is likely to be due to the following reasons: i) the cut off points used in the different definitions; and ii) inconsistency in the number of elements required by each definition. Consequently, a general and diagnostic definition is required for planning early prevention and for the identification of MetS-susceptible PCOS patients. It is also unclear which definition(s) is/are the best. Some of the previously conducted studies have reported the ATP III to be better than the IDF criteria, in terms of prediction.^[@R66],[@R67]^ In contrast, Tong et al. highlighted the inability of the IDF definition for identifying MetS patients with a high risk of coronary heart disease.^[@R68]^

Previous research has reported that the relationship between PCOS and MetS to be independent of age. In support of previous research, we also found that the heterogeneity in the relationship between PCOS and MetS could not be explained by the participants' age. Similarly, Vural et al indicated a higher frequency of MetS among women with PCOS in all age groups.^[@R62]^ In contrast, a cross-sectional study reported MetS prevalence of 12.1% for women aged 20-24 years old, 31.7% among 25-29 year olds and 42.9% among those aged 30-34 years old.^[@R47]^ Also, several other studies have found the prevalence of MetS to be heavily age-dependent.^[@R69],[@R70]^ A higher risk of MetS has also been reported among women under 30 years old with PCOS, which highlights the importance of early and regular screening for MetS among young women with PCOS.^[@R65]^

In our study the prevalence of MetS components (e.g. WC, and HTN) were estimated among women with PCOS. This found a high prevalence of WC among these women (52.23%). In previous research, the prevalence of obesity in women with PCOS has been reported to be 30%--75%,^[@R71],[@R72]^ which is extremely high and demonstrates the strong effect of adiposity on the development and maintenance of PCOS.^[@R73]^

The current study also found that the various indicators of MetS, such as high levels of TG and FBS and a low HDL level, were more prevalent among women with PCOS than among the healthy controls. This finding supports previous research which has also found higher rates of MetS components among women with PCOS, than among healthy controls.^[@R35],[@R74],[@R75]^ For instance, research in India found a dyslipidemia rate of 90.2% among adolescent women with PCOS and 21.6% of their sample had high levels of FBS.^[@R35]^ Furthermore, a meta-analysis found higher levels of low-density lipoprotein in women with PCOS, than among healthy controls.^[@R74]^ Several studies have also reported dyslipidemia to be the most frequently identified indicator of metabolic disorder among patients with PCOS, with prevalence rates of up to 70% being reported.^[@R5],[@R12],[@R75]^ The high prevalence of this symptom is thought to be as a result of changes in the concentration of several hormones (insulin, estrogens, and androgens) among women with PCOS, which alters the metabolism of lipoproteins.^[@R76]^ In an effort to remove excess hyperandrogenism and estrogen in women with PCOS, using gonadotrophin‐releasing hormone agonists (GnRHa), research found that after three months of treatment androgen and estrogen levels were reduced and a slight reduction was also found in the levels of triglyceride.^[@R77]^ In contrast, Pirwany et al indicated that metabolic disorder was more closely related to adiposity/insulin metabolism than to circulating androgen levels.^[@R78]^ In general, because of a higher prevalence of dyslipidemia among the PCOS patients, it is important that the levels of serum lipids should be carefully monitored.

This study is a comprehensive systematic review and meta-analysis on the prevalence of MetS, and its components, among women diagnosed with PCOS. An extensive search of 10 databases was made in order to avoid missing any relevant information. However, as with any study this meta-analysis and systematic review had a number of strengths and limitations. The first strength of this study was the comprehensive search strategy which covered 10 databases. In addition, the search and data extraction processes were conducted independently by two authors, reducing the chances that something would be missed. Furthermore, the prevalence of MetS was presented by calculating the ORs using different diagnostic criteria, rather than relying solely on one. Finally, another strength of the study was that the possible sources of heterogeneity across studies were examined using a series of meta-regression analyses.

This study also had a number of limitations, including the fact that non-English studies were not included and that surprisingly there were no studies identified from Africa. Finally, due to sparse data bias, subgroup analysis on the different variables could not be undertaken.

Conclusion {#s5}
==========

The present study found that women with PCOS had a much higher prevalence of MetS than was found among healthy controls. Therefore, the present study highlights the importance of preventive strategies designed to prevent MetS among women with PCOS. Furthermore, as low HDL and high WC were the most commonly identified components of MetS, among women diagnosed with PCOS, these two components particularly need to be carefully addressed in prevention strategies.
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